CN101429251B - Anti-tumor fusion protein, preparation method and application thereof - Google Patents

Anti-tumor fusion protein, preparation method and application thereof Download PDF

Info

Publication number
CN101429251B
CN101429251B CN2007101663115A CN200710166311A CN101429251B CN 101429251 B CN101429251 B CN 101429251B CN 2007101663115 A CN2007101663115 A CN 2007101663115A CN 200710166311 A CN200710166311 A CN 200710166311A CN 101429251 B CN101429251 B CN 101429251B
Authority
CN
China
Prior art keywords
muc1
hsp65
vntr
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007101663115A
Other languages
Chinese (zh)
Other versions
CN101429251A (en
Inventor
郑玉玲
江华
姜永强
郝淮杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Microbiology and Epidemiology of AMMS
Original Assignee
Institute of Microbiology and Epidemiology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Microbiology and Epidemiology of AMMS filed Critical Institute of Microbiology and Epidemiology of AMMS
Priority to CN2007101663115A priority Critical patent/CN101429251B/en
Publication of CN101429251A publication Critical patent/CN101429251A/en
Application granted granted Critical
Publication of CN101429251B publication Critical patent/CN101429251B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention discloses an anti-tumor fusion protein, which contains two tandem repeat sequences VNTR of a tubercle bacillus heat shock protein HSP65 and a human mucin MUC12. The invention also discloses a preparation method of the fusion protein, which comprises the steps of obtaining HSP65 protein coding gene and preparing human MUC1 protein single tandem repeat VNTR1Preparation of HSP65-MUC1 VNTR1Gene and preparation of HSP65-MUC1 VNTR2Recombinant expression vector and expression of geneHSP65-MUC1 VNTR2Fusion protein and the like. The invention also discloses the application of the fusion protein in tumor resistance. The fusion protein can inhibit the growth of MUC1 positive tumor cells, and has wide application prospect.

Description

A kind of antineoplastic amalgamation protein, Preparation Method And The Use
Technical field
The present invention relates to a kind of fusion rotein, be specifically related to the fusion rotein of a kind of people of containing MUC1, also relate to the encoding sox of this fusion rotein, and the preparation method of this fusion rotein and medical use.
Background technology
Mucoprotein 1 (MUC1) is that a kind of molecular weight is greater than linear transmembrane glycoprotein (the Meseguer M of the macromole of 200KD; Pellicer A; Simon C.MUC1 and endometrial receptivity [J] .Molecular HumanReproduction, 1998,4 (12): 1089-1098.); Be distributed widely in multiple epithelioglandular nearly tube chamber faces such as mammary gland, ovary, respiratory tract, gi tract, urogenital system, be polar contribution.At canceration surface epithelial cell height unconventionality expression; And corresponding change takes place in structure; Its polypeptide core extracellular fragment contains 20 amino acid whose tandem repetitive sequences, and (Variable numbers tandem repeats, VNTR), this sequence number does not wait from 30 to 200.Discover; Can produce to the specific immune reaction CTL identification epi-position of expressing the MUC1 tumour cell in mouse and the human body and be positioned at VNTR (Jerome K R; Bamd DL; Bendt K M; Et al.Cytotoxic T lymphocytes derived from patients with breast adenocarcinoma recognize anepitope present on the protein core of a mucin molecule preferentially expressed by malignantcells [J] .Cancer Res.1991,51 (11): 2908-2916; Apostolopoulos V, Loveland B E, Pietersz G A, et al.CTL in mice immunized with human mucin 1 are MHC-restricted [J] .J Immunol.1995,155 (11): 5089-5094.).Mycobacterium tuberculosis heat shock protein(HSP) 65 (HSP65) belongs to HSP70 family; Very strong immunogenicity (Silva C L is arranged; Lowrie D B.A single mycobaterial protein (HSP65) expressedby a transgenic antigen-presenting cell vaccinates mice against tuberculosis [J] .Immunology; 1994,82 (2): 244-248.).Discovering Mycobacterium tuberculosis heat shock protein(HSP) 65 in recent years; Independent HSP65 albumen can inducing antitumor immunity, suppresses growth of tumor, but it produces nonspecific immune response and realize through inducing inhibition of tumour; Its tumor-inhibiting action produces fast; But a little less than the effect, the time of keeping is also shorter, and is therefore unsatisfactory to the final inhibition effect of tumour.(Li?D?P，Li?H，Zhang?P?Y，et?al.Heat?shock?fusion?protein?induces?both?specific?and?nonspecificanti-tumor?immunity[J].Eur?J?Immunol，2006，36(5)：1324-1336.)。
Recent study is found, heat shock protein(HSP) 65 (HSP65)-MUC1 epitope peptide fusion rotein (HSP65-MUC1), and (Mucin 1 to stimulate body to produce tumour antigen mucoprotein 1; MUC1) specificity cell toxicity T lymphocyte (CTL); Suppress the growth of MUC1 positive tumor, therefore become tumor vaccine (Wang Xueju, the Wang Zhibo of treatment and prevention MUC1 high expression level tumour; Wei Hongfei; Deng the enhancement [J] of .C type CpG single stranded oligonucleotide to the tumor vaccine tumor killing effect. cell and molecular immunology magazine, 2007,23 (4): 338-342.).Further research shows that heat-shock protein-polypeptide compound can intersect through antigen and offer to get into endogenous antigen and offer approach; Activate to special cellullar immunologic response (the Castellino F of antigen peptide; Boucher P E; Eichelberg K; Et al.Receptor-mediated up take of Antigen:Heatshock protein complexes results in major histo-compatibility complex class I antigenpresentation via two distinct processing pathways [J] .J Exp Med, 2000,11 (191): 1957-1964.); Its reason possibly be that HSP65 has activated fast nonspecific immunity and replys, and has activated persistent specific immunoreation through albumen or the peptide that merges then.
Summary of the invention
For more efficiently tumor prevention and treatment biotechnological formulation are provided, the present invention discloses a kind of new antitumoral fusion rotein HSP65-MUC1 VNTR according to above-mentioned principle 2, this fusion rotein contains heat shock protein(HSP) HSP65 and 2 tandem repetitive sequence VNTR of the mucoprotein MUC1 polypeptide nuclear core extracellular fragment of people of tubercule bacillus 2VNTR wherein 2Aminoacid sequence is: HMSTAPPAHGVTSAPDTRPAPGSTAPPEFSTAPPAHGVTSAPDTRPAPGSTAPP; See sequence 1 in the sequence table; Its gene coded sequence is CATATGTCTACCGCTCCGCCGGCTCACGGTGTTACCTCTGCTCCGGACACCCGTCC GGCTCCGGGTTCTACCGCTCCGCCGGAATTCTCTACCGCTCCGCCGGCTCACGGTG TTACCTCTGCTCCGGACACCCGTCCGGCTCCGGGTTCTACCGCTCCGCCG, sees sequence 10 in the sequence table.The BCG-CWS tubercle bacillus gene group that the encoding sox of HSP65 is announced referring to GenBank in the fusion rotein of the present invention (hsp65 genehttp: //www.ncbi.nlm.nih.gov/entrez/viewer.fcgi? Cmd=Retrieve&db=Nucleotide&list_uids=149999&dopt=GenBank kLNWctdl_63Oj16anVsEDsVlo5ph6x%40255F5A486FDBC4B0_0067SI D&WebEnvRq=1) and the research (Xiao Ling of Xiao Ling etc.; Wei Yazhi; Xia Fei; Deng. the preparation [J] of the structure of tubercule bacillus Hsp65 and EGFP fusion gene and DC vaccine. cell and molecular immunology magazine; 2005,21 (1): 13-16.).
The invention also discloses the recombinant expression vector of expressing above-mentioned fusion rotein, this carrier contains the tandem repetitive sequence VNTR2 of tubercule bacillus heat shock protein(HSP) HSP65 and the mucoprotein MUC1 of people.This recombinant vectors can select prokaryotic expression carrier, preferred pET28a (+).
The invention also discloses HSP65-MUC1 VNTR 2The preparation method of fusion rotein comprises the steps:
At first be obtaining of BCG HSP65 encoding sequence.The upstream and downstream primer of research and design tubercule bacillus heat shock protein(HSP) 65 genes of BCG-CWS tubercle bacillus gene group of announcing according to GenBank and Xiao Ling etc.Cultivate the BCG-CWS tubercule bacillus with the logical potato culture of Soviet Union, extract the tubercle bacillus gene group.With the genome is template, and amplification obtains the HSP65 full length gene, is connected to cloning vector; Carry out double digestion, subclone is to expression vector then, and this expression vector can be prokaryotic expression carrier; Preferred pET28a (+), cloning vector can be the T carrier, wherein preferred pMD18-T.
Be the preparation of the proteic single Tumor-necrosis factor glycoproteins VNTR1 of people MUC1 then.VNTR sequence (the http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi of the people MUC1 that announces according to GenBank? Cmd=Retrieve&db=Nucleotide&list_uids=37053&dopt=GenBank& WebEnv=0LRqGB9Y1EV-m5vbaRsN8Qzq1NmK8QKExjjwwV9gU8ycMSdbJ _ cXMAp4ba--16nCdD3kFfqrAoy_X_%40255F5A486FDBC4B0_0067SID& WebEnvRq=1), optimization design upstream and downstream splicing primer.The single Tumor-necrosis factor glycoproteins that splices the MUC1 VNTR that is carried out pcr amplification with different primers respectively.The PCR product that amplifies is carried out gel respectively reclaim the back and be connected with the pMD18-T carrier, will connect product Transformed E .coli then, the extracting DNA is cut through PCR and enzyme and to be accredited as male and to clone and check order.
Carry out HSP65-MUC1 VNTR then 2-pET28a construction of recombinant plasmid.Correct MUC1 VNTR is identified in order-checking 1-pMD18-T positive colony extracts plasmid.Earlier to MUC1VNTR 1-pMD18-T plasmid and HSP65-pET28a plasmid carry out double digestion, and the purifying and recovering enzyme is cut product, again with the MUC1 VNTR of T4 ligase enzyme with recovery 1Gene is connected with HSP65-pET28a.To connect product Transformed E .coli then, through PCR and enzyme cut identify correct after, the extracting plasmid is to HSP65-MUC1VNTR 1-pET28a plasmid and MUC1 VNTR 1-PMD 18-T carries out double digestion, the samely enzyme is cut product reclaims connection.Connect product Transformed E .coli, cut through PCR and enzyme that to be accredited as the male recon be HSP65-MUC1 VNTR 2-pET28a extracts plasmid Transformed E .coli.HSP65-MUC1VNTR 2-pET28a makes up synoptic diagram and sees accompanying drawing 3.
Then carry out HSP65-MUC1 Expression of Fusion Protein and purifying.To contain expression plasmid HSP65-MUC1 VNTR 2The E.coli of-pET28a cultivates, and adds IPTG and induces.Centrifugal then collection thalline carries out ultrasonication, gets supernatant after centrifugal; Appearance is gone up to the Q post, then with the target protein wash-out in supernatant dilution back.The concentrated target protein elutriant that contains, last appearance is to Saphacryl TmThe s-200 gel column, wash-out.
HSP65-MUC1VNTR 2Proteic Western blot detects.The equal conditions inductive is contained expression plasmid HSP65-MUC1 VNTR 2After handling simultaneously, the E.coli of-pET28a and plasmid pET28a carries out the SDS-PAGE electrophoresis.After electrophoresis finishes, albumen being transferred to pvdf membrane, is one anti-with the mouse-anti people MUC1mAb that buys, and the sheep anti mouse of HRP mark is two anti-, to expressed HSP65-MUC1 VNTR 2Albumen carries out Western blot and detects.Through detecting, prove that the fusion rotein that is obtained is HSP65-MUC1VNTR 2
The invention also discloses HSP65-MUC1VNTR 2The anticancer usage of fusion rotein.With HSP65-MUC1VNTR disclosed by the invention 2Fusion rotein with auxiliary material combinations such as suitable dilution agent, excipient, can prepare the antitumor drug of various formulations as activeconstituents.Pharmaceutical dosage form is preferably injection.The present invention is through experimentation on animals, in the mouse body to HSP65-MUC1VNTR 2The tumor inhibition effect of fusion rotein has carried out preliminary study.Research shows that the tumor killing effect of generation is better through multiple spot subcutaneous injection administration.Albumen dosage is carried out the gradient experiment to be found; The fusion rotein of high dosage (10 μ g/ only) and low dosage (2.5 μ g/ only) all can suppress the growth of MUC1 positive tumor; But than high dose group, low dosage more can effectively suppress tumor growth, has compared utmost point significant difference with control group.The high dosage inhibiting rate that this result shows is lower than low dosage and possibly causes that immunological tolerance is relevant with it.The present invention has carried out preventative research to the effect of the inhibition MUC1 male tumour cell of HSP65-MUC1 fusion rotein; Result of study shows can reach 72% to MUC1 positive B 16 cell inhibiting rates; Even there is 50% mouse not see tumor growth; And the tumor formation rate of control group is 100%, and the tumor suppression effect is obvious.The present invention can stimulate mouse to produce cellullar immunologic response through discovering HSP65-MUC1 VNTR2 fusion rotein, thus the anti-BA of expressing the tumor growth of MUC1 of performance, and the tumor growth of MUC1 is expressed in inhibition.Tracing it to its cause possibly be that HSP65 has activated fast nonspecific immunity and replys, and has activated persistent specific immunoreation through albumen or the peptide that merges then.The malignant tumor patient of therefore, based on the HSP65 peptide fusion protein of taa MUC1 epidermis being originated will be a kind of treat-ment very likely.
The present invention utilizes prokaryotic expression system, cuts, is connected with enzyme through gene overlap, makes up HSP65-MUC1 VNTR 2-pET28a expression vector with 2 repeated fragments and the HSP65 gene fusion of VNTR in the people MUC1 gene, is induced through IPTG and to be realized HSP65-MUC1 VNTR 2The simple, fast and efficient solubility expression of fusion rotein in e. coli bl21 (DE3).The expression strain E.coli.BL21 (DE3) that adopts in this research is the gene of cloning by expression on the PET serial carrier efficiently; Bacterial strain E.coli BL21 (DE3) lacks the lon proteolytic enzyme and the ompT outer membrane protein enzyme of protein degradation in the purge process simultaneously, and expressed target protein has advantages of higher stability.Fusion rotein HSP65-MUC1 VNTR2 disclosed by the invention is high in the expression in escherichia coli amount; The target protein expression amount accounts for more than 60% of whole bacterial protein content, and (Hu Rong is based on the research of the therapeutic vaccine of the MUC1 of heat shock protein(HSP) to be higher than expression amount in the reported in literature; The 51st page of 2002 grades of Military Medical Science Institute's master thesis); The document adopts identical expression system, and the expressing quantity of the HSP65-MUC1 VNTR1 of preparation is lower, only accounts for 30% of whole bacterial protein.In addition; Fusion rotein HSP65-MUC1 VNTR2 is a solubility expression; Well kept this fusion rotein active; Obtain the HSP65-MUC1 VNTR2 fusion rotein of purity more than 95% easily in conjunction with simple purification procedures, it is folding that the sequence that this fusion rotein is described is beneficial to the space, and BA is good.Consider the bigger present situation of clinical required dosage of this series products, adopt fusion rotein sequence of the present invention and expression system to be easy to prepare this fusion rotein of clinical dosage, be beneficial to industrialization production.
The present invention also estimates to the restraining effect of MUC1 positive tumor cell this fusion rotein.To the bio-evaluation of fusion rotein of the present invention, find that it can activate MUC1 peptide specific cellullar immunologic response in vivo, suppress the growth of MUC1 male tumour cell, to compare with documents, this fusion rotein has unique tumor suppression effect.Albumen dosage is carried out the gradient experiment find, the fusion rotein of low dosage (2.5 μ g/ only) can effectively suppress tumor growth, obtains best tumor suppression effect.2.5 a μ g/ dose groups to mouse inoculation cell count up to (2～3) * 10 6The tumour inhibiting rate of the positive B16 cell of individual MUC1 can reach 72%, and anticancer effect is superior to other HSP65-MUC1 fusion rotein of Isodose.And in the documents, the cell count of every mouse inoculation is few, is 1 * 10 5The positive B16 cell of individual MUC1 is only just obtained best tumor suppression effect at high dosage 40 μ g/.(Eur?J?Immunol，2006，36(5)：1324-1336.)。Therefore, it is lower that fusion rotein of the present invention is obtained the required dosage of best tumor suppression effect, possibly have better potential applicability in clinical practice.
Description of drawings
Fig. 1 is pcr gene amplification figure.
Wherein A is the pcr amplification of HSP65 gene, the 1:HSP65 gene; 2: negative control; 3: positive control; M:DL 2000;
B is MUC1 VNTR 1Splicing (Splicing) PCR, 1: the contrast; 2:MUC1 VNTR 1Gene; M:DL2000;
C is recombinant vectors HSP65-MUC1 VNTR 2Restriction analysis, 1:Nde I+Hind III double digestion HSP65-MUC1 VNTR 2-PET28a; M:DL2000
Fig. 2 is HSP65-MUC1 VNTR 2Protein expression, purifying is schemed with identifying.Wherein
A is fusion rotein HSP65-MUC1 VNTR 2Expression in E.coli, 1:BL21/HSP65-MUC1 VNTR 2-pET28a positive colony; The 2:BL21/pET28a negative control; M: LMWP marker;
B is protein HSP65-MUC1VNTR 2Purifying, 1: full cell lysate; 2: purified proteins matter HSP65-MUC1 VNTR 2M: LMWP marker;
C is protein HSP65-MUC1 VNTR 2Western blot analyze the SDS-PAGE of 1:BL21/pET28a negative control; 2:HSP65-MUC1 VNTR 2SDS-PAGE; The Western blot of 3:BL21/pET28a analyzes; 4:HSP65-MUC1 VNTR 2Western blot analyze; M: LMWP marker
Fig. 3 is HSP65-MUC1 VNTR 2-pET28a makes up synoptic diagram.
Embodiment
Embodiment 1 HSP65-MUC1 VNTR 2Expression of Fusion Protein
One. material
Bacterial strain, cell strain and plasmid bacterial strain E.coli DH5 α, E.coli BL21 (DE3), expression plasmid pET28a (+), stable transfection people MUC1 mouse B16 cell (Eur J Immunol, 2006,36 (5): 1324-1336.); Cloning vector pMD18-T, LA Taq enzyme, restriction endonuclease NcoI, NdeI, EcoRI, Hind III, T4 dna ligase, DNA marker DL2000 are available from TaKaRa company.Bacterial genomes DNA extraction test kit TIANamp Bacteria DNA Kit is a Time Inc. available from the sky; The plasmid extraction test kit is available from Axygen Biosciences company; Sc-7313 is available from Zymed company for mouse-anti people MUC1 monoclonal antibody (mAb); The sheep anti-mouse antibody of horseradish peroxidase (HRP) mark is available from Bioisystech Co., Ltd of middle China fir Golden Bridge; The low Mr Marker of protein rises positive Bioisystech Co., Ltd available from Shanghai; Glue reclaims test kit available from the general biotechnology center in road, Beijing.Experiment mice is C57BL/6, and is female, quality 18～22g, and the SPF level is available from Military Medical Science Institute's Experimental Animal Center.
Two. method
1.BCG obtaining of HSP65 encoding sequence
The upstream primer of research and design tubercule bacillus heat shock protein(HSP) 65 genes of BCG-CWS tubercle bacillus gene group of announcing according to GenBank and Xiao Ling etc.: 5 '-GGC ccatgg CCAA GACAA TTGCG-3 ' (containing Nco I restriction enzyme site) shown in sequence in the sequence table 2, downstream primer: 5 '-GGC catatg CATGCCACCCAT-3 ' (containing the NdeI restriction enzyme site) is shown in sequence in the sequence table 3.Cultivate the BCG-CWS tubercule bacillus, extraction tubercle bacillus gene group with the logical potato culture of Soviet Union in 37 ℃～39 ℃.With the genome is template, and pcr amplification obtains the HSP65 full length gene, and reaction system is 50 μ l, after reaction conditions is 95 ℃ of preparatory sex change 5min, and 94 ℃ of sex change 1min, 59 ℃ of renaturation 1min, 72 ℃ are extended 1min, 35 circulations, 72 ℃ are extended 7min.The HSP65 gene that pcr amplification is obtained carries out glue recovery purified pcr product with E.Z.N.A Gel extraction kit after 1% agarose electrophoresis is identified; Be connected to the pMD18-T carrier; Reaction system is 10 μ L; Dna fragmentation and pMD18-T carrier mol ratio are 10: 1,16 ℃ of connections of spending the night., cultivate the back and extract plasmid the HSP65-pMD18-T cloning vector transformed competence colibacillus cell DH5 α that obtains by ordinary method, order-checking is identified correct, carries out double digestion with NcoI and NdeI, and subclone is to prokaryotic expression carrier pET28a (+).
2. the acquisition of the single Tumor-necrosis factor glycoproteins of people MUC1 albumen VNTR
The VNTR sequence of the people MUC1 that announces according to GenBank, establish upper reaches meter splicing primer: 5 '-TCTACCGCTCCGCCGGCTCACGGTGTTACC TCTGCTCCGGACACC-3 ' (seeing sequence 4 in the sequence table), downstream splicing primer: 5 '-CGGCGGAGCGGTAGAACCAGGAGCAGGACG GGTGTCCGGAGCAGA-3 ' (seeing sequence 5 in the sequence table), wherein line part is an overlap.The single Tumor-necrosis factor glycoproteins that splices the MUC1 VNTR that is carried out pcr amplification with 2 groups of primers respectively.The 1st group of upstream primer: 5 '-GGGTTAAC catatg TCTACCGCTCCGCCGGCTCAC-3 ' (seeing sequence 6 in the sequence table) (containing the NdeI restriction enzyme site), downstream primer: 5 '-CG gaattc CGGCGGAGCGGTAGAACCAGG-3 ' (seeing sequence 7 in the sequence table) (containing EcoR I restriction enzyme site); The 2nd group of upstream primer: 5 '-GGGTTAAC gaattcTCTACCGCTCCGCCGGCTCAC-3 ' (seeing sequence 8 in the sequence table) (containing EcoR I restriction enzyme site), downstream primer: 5 '-CG aagctt TTA CGGCGGAGCGGTAGAACCAGG-3 ' (seeing sequence 9 in the sequence table) (containing Hind III restriction enzyme site).The PCR product that amplifies is carried out back the connection in 16 ℃ with pMD18-T carrier (mol ratio 10: 1) of gel recovery respectively to spend the night; 10 μ L are connected product Transformed E .coli DH5 α; The extracting DNA is cut through PCR and enzyme and to be accredited as the male clone and to send the order-checking of three rich biotech firms.
The PCR reaction system is 50 μ L, and reaction conditions is 94 ℃ of preparatory sex change 5min, 94 ℃ of sex change 30s, and 59 ℃ of renaturation 30s, 72 ℃ are extended 20s, 25 circulations, 72 ℃ are extended 7min.
3.HSP65-MUC1 VNTR 2-pET28a construction of recombinant plasmid
Correct MUC1 VNTR is identified in order-checking 1-pMD18-T positive colony carries out plasmid according to the plasmid extraction kit operation instructions and extracts.Earlier with NdeI, EcoRI to containing the MUC1 VNTR of NdeI, EcoRI restriction enzyme site 1-pMD18-T plasmid and HSP65-pET28a plasmid carry out double digestion 4h, and the purifying and recovering enzyme is cut product, again with the MUC1 VNTR of T4 ligase enzyme to reclaiming 1Gene spends the night in 16 ℃ with HSP65-pET28a (mol ratio 10: 1) and is connected.10 μ L are connected product Transformed E .coli DH5 α, through PCR and enzyme cut identify correctly after, extracting plasmid again is with EcoRI, the extractive HSP65-MUC1VNTR of Hind III 1-pET28a plasmid and the MUC1VNTR that contains EcoRI, Hind III restriction enzyme site 1-PMD18-T carries out double digestion, and enzyme is cut product and as above reclaimed, and connects.Connect product Transformed E .coli DH5 α, cut through PCR and enzyme that to be accredited as the male recon be HSP65-MUC1VNTR 2-pET28a extracts plasmid Transformed E .coli BL21 (DE3).
4.HSP65-MUC1 Expression of Fusion Protein and purifying
To contain expression plasmid HSP65-MUC1 VNTR 2The E.coli BL21 (DE3) of-pET28a is cultured to logarithmic phase in 30 ℃, adds IPTG to final concentration 1mmol/L, induces 4h.The centrifugal 10min of 8000r/min collects thalline, with the resuspended deposition of aseptic 5mmol/L PB, and the ultrasonication intestinal bacteria, 4 ℃, 12, the centrifugal 10min of 000r/min gets supernatant; With 5mmol/L PB pH7.2 with 4 times of supernatant dilutions after, last appearance is extremely with the Q post of 5mmol/L PB pH7.2 pre-equilibration, the damping fluid that contains 500mmol/LNaCl with 5mmol/L PB again is with the target protein wash-out.Contain and go up appearance to Saphacryl after the target protein elutriant concentrates TmThe s-200 gel column contains 150mmol/LNaCl pH7.0 wash-out with 50mmol/L PB.
Three. the result
1. Mycobacterium tuberculosis HSP65 gene amplification is template with the Mycobacterium tuberculosis genome, at the 1600bp place one bright band is arranged through electrophoresis showed through pcr amplification, conforms to purpose fragment (1623bp) size (Figure 1A).The obtained fragment was inserted into pMD18-T vector and sequenced after the show and in GenBank mycobacterial heat shock protein 65 gene sequences (hsp65? Genehttp :/ / www.ncbi.nlm.nih.gov / entrez / viewer.fcgi ? cmd = Retrieve & db = Nucleotide & list_uids = 149999 & dopt = GenBank & WebEnv = 0Wv7VvoPbtVWCqYZSu5q1dhVPJAjickJmp84Z2tqGvw_O_o3kLNWctdl_63Oj16anVsEDsVlo5ph6x% 40255F5A486FDBC4B0_0067SID & WebEnvRq = 1) consistent.
2. overlapping PCR obtains people MUC1 VNTR 1Sequence
Utilize overlapping PCR to obtain MUC1 VNTR 1After the fragment, more respectively to MUC1 VNTR 1Fragment is carried out pcr amplification, and the result carries out agarose gel electrophoresis, and being presented at 100bp has a bright band (Figure 1B), conforms to A purpose fragment (97bp) size; Checking order the fragment insertion pMD18-T carrier that obtains afterwards, its gene coded sequence of demonstration is GGGTTAACCATATGTCTACCGCTCCGCCGGCTCACGGTGTTACCTCTGCTCCGGAC ACCCGTCCGGCTCCGGGTTCTACCGCTCCGCCGGAATTCCG.
3.HSP65-MUC1 VNTR 2Expression and the purifying of albumen in intestinal bacteria
The MUC1 VNTR that order-checking is correct 1After-pMD18-T plasmid and HSP65-pET28a plasmid such as method are partly carried out 2 endonuclease digestions, are connected and transformed DH5 α; The single positive bacterium colony extraction plasmid of picking carries out enzyme with Nde I, Hind III and cuts evaluation; The result shows the positive, and HSP65-MUC1VNTR is described 2-pET28a protokaryon construction of recombinant expression plasmid is accomplished (Fig. 1 C).Behind recombinant plasmid transformed E.coliBL21 (DE3); After IPTG induces, carry out the SDS-PAGE electrophoresis, the Coomassie brilliant blue coloration result shows; The negative control that only contains empty carrier with the equal conditions inductive is compared; Positive colony has the band (Fig. 2 A) of clauses and subclauses at the Mr66000 place, the target protein expression amount accounts for more than 60% of whole bacterial protein content, is that expression amount is the highest in the reported in literature.Behind Q post and gel-filtration purifying, obtain purity higher H SP65-MUC1 VNTR 2Fusion rotein, purity of protein is at (Fig. 2 B) more than 95%.
Embodiment 2 HSP65-MUC1 VNTR 2Detection of fusion proteins
One, material: with embodiment 1.
Two, method: adopt Western blot method to HSP65-MUC1 VNTR 2Fusion rotein detects.The equal conditions inductive is contained expression plasmid HSP65-MUC1 VNTR 2The E.coli BL21 (DE3) of-pET28a and plasmid pET28a respectively gets 200 μ L, carries out the SDS-PAGE electrophoresis after handling simultaneously.After electrophoresis finishes, albumen being transferred to pvdf membrane, is one anti-with the mouse-anti people MUC1 mAb sc-7313 (1: 500) that buys, and the sheep anti mouse of HRP mark (1: 2000) is two anti-, to expressed HSP65-MUC1 VNTR 2Fusion rotein carries out Western blot checking.
Three, result: anti-expressed albumen is identified as with mouse-anti people MUC1mAb sc-7313; With the bacterial strain that only contains the pET28a empty plasmid as negative control; The result is presented at Mr 66000 places, and to contain the bacterial strain of expression plasmid positive; And negative control does not have band (Fig. 2 C) to occur, explains that the target protein of expressing contains MUC1 VNTR 2
Embodiment 3 HSP65-MUC1 VNTR 2Fusion rotein tumor prevention experiment in animal body
One, material: with embodiment 1.
Two, method: tested the 0th day, with 30 C57BL/6 mouse be divided at random 10 μ g/ only, 2.5 μ g/ only 2 dose groups and saline water control group, 10 every group, every mouse administration volume 0.2ml.Respectively at the 1st, 8,22 day outside of belly four limbs subcutaneous administration, got in the 29th day and to be inoculated in the 13rd day MUC1-B16 cell burrknot of C57BL/6 mouse, grind, dilute at 1: 6 with aseptic PBS, be mixed with tumor cell suspension, cell count is (2～3) * 10 6The individual administration group mouse right fore that is inoculated in is subcutaneous.In the 41st～44 day, put to death mouse, cut open and get the tumour of respectively organizing mouse, weigh the tumour inhibiting rate of each group of statistics.Tumour inhibiting rate=(1-experimental group knurl weight-average value/control group knurl weight-average value) * 100%.Tumour inhibiting rate is carried out homogeneity test of variance and variance test, and significant difference is with P＜0.05 expression, and utmost point significant difference is with P＜0.01 expression.Used statistical software is SPSS13.0.
Three, result: the 14th day execution mouse claims that knurl is heavy behind inoculated tumour; The result is carried out statistical analysis, and the result shows that the MUC1-B16 growth of tumor has received obvious inhibition to 2.5 a μ g/ dose groups; Average tumor is about 0.5g; Tumor control rate has reached 72.08%, has compared extremely significant difference (p＜0.01) with control group, when experiment finishes, has 50% (5) mouse not see tumor growth.When 10 a μ g/ dose groups finished in experiment, average knurl heavily was about 1.17g, and inhibiting rate is about 37%, and comparing with control group does not have significant difference (p＞0.05).The average knurl of saline water group focuses on when experiment finishes and reaches 1.877g, explains that tumor growth is good.
Sequence table
< 110>Inst. of Epidemiology and Microbiology, Academy of Military Medical Sciences, PL
< 120>a kind of antineoplastic amalgamation protein, Preparation Method And The Use
<130>
<160>10
<170>PatentIn?version?3.2
<210>1
<211>54
<212>PRT
<213>
<400>1
His?Met?Ser?Thr?Ala?Pro?Pro?Ala?His?Gly?Val?Thr?Ser?Ala?Pro?Asp
1 5 10 15
Thr?Arg?Pro?Ala?Pro?Gly?Ser?Thr?Ala?Pro?Pro?Glu?Phe?Ser?Thr?Ala
20 25 30
Pro?Pro?Ala?His?Gly?Val?Thr?Ser?Ala?Pro?Asp?Thr?Arg?Pro?Ala?Pro
35 40 45
Gly?Ser?Thr?Ala?Pro?Pro
50
<210>2
<211>23
<212>DNA
<213>
<400>2
ggcccatggc?caagacaatt?gcg 23
<210>3
<211>21
<212>DNA
<213>
<400>3
ggccatatgc?atgccaccca?t 21
<210>4
<211>45
<212>DNA
<213>
<400>4
tctaccgctccgccggctcacggtgttacctctgctccggacacc 45
<210>5
<211>45
<212>DNA
<213>
<400>5
cggcggagcggtagaaccaggagcaggacgggtgtccggagcaga 45
<210>6
<211>35
<212>DNA
<213>
<400>6
gggttaac?catatg?tctaccgctccgccggctcac 35
<210>7
<211>29
<212>DNA
<213>
<400>7
cg?gaattc?cggcggagcggtagaaccagg 29
<210>8
<211>35
<212>DNA
<213>
<400>8
gggttaac?gaattc?tctaccgctccgccggctcac 35
<210>9
<211>32
<212>DNA
<213>
<400>9
cg?aagctt?tta?cggcggagcggtagaaccagg 32
<210>10
<211>162
<212>DNA
<213>
<400>10
catatgtcta?ccgctccgcc?ggctcacggt?gttacctctg?ctccggacac?ccgtccggct 60
ccgggttcta?ccgctccgcc?ggaattctct?accgctccgc?cggctcacgg?tgttacctct 120
gctccggaca?cccgtccggc?tccgggttct?accgctccgc?cg 162

Claims (6)

1. antineoplastic amalgamation protein HSP65-MUC1VNTR 2, it is characterized in that two tandem repetitive sequence VNTR by tubercule bacillus heat shock protein(HSP) HSP65 and the mucoprotein MUC1 of people 2Form VNTR 2Aminoacid sequence see sequence 1 in the sequence table.
2. fusion rotein according to claim 1, wherein VNTR 2Gene order see sequence 10 in the sequence table.
3. recombinant expression vector of expressing claim 1 or 2 said fusion roteins is characterized in that containing the tandem repetitive sequence VNTR of tubercule bacillus heat shock protein(HSP) HSP65 and the mucoprotein MUC1 of people 2
4. according to the said recombinant expression vector of claim 3, expression vector wherein is prokaryotic expression carrier pET28a (+).
5. claim 1 or 2 said fusion roteins are in the purposes of preparation in the anti-MUC1 positive tumor medicine.
6. according to the said purposes of claim 5, wherein said pharmaceutical dosage form is an injection.
CN2007101663115A 2007-11-06 2007-11-06 Anti-tumor fusion protein, preparation method and application thereof Expired - Fee Related CN101429251B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2007101663115A CN101429251B (en) 2007-11-06 2007-11-06 Anti-tumor fusion protein, preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2007101663115A CN101429251B (en) 2007-11-06 2007-11-06 Anti-tumor fusion protein, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN101429251A CN101429251A (en) 2009-05-13
CN101429251B true CN101429251B (en) 2012-05-23

Family

ID=40644912

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007101663115A Expired - Fee Related CN101429251B (en) 2007-11-06 2007-11-06 Anti-tumor fusion protein, preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN101429251B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101967193B (en) * 2010-03-19 2016-03-30 上海医学生命科学研究中心有限公司 The Hsp60 fragment that can be combined with LOX-1, its derivative and application
CN106279435B (en) * 2016-08-16 2019-06-07 新乡医学院 Target anti-tumor vaccine, encoding gene, expression vector, expression engineering bacteria and the application of VEGF and mucin1
CN107158375A (en) * 2017-07-21 2017-09-15 台桂香 Purposes of the CpG composite adjuvants in MUC1 fusion proteins are antitumor
CN107349425A (en) * 2017-07-21 2017-11-17 台桂香 Applications of the CpG ODN in MUC1 fusion proteins are antitumor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0841400A1 (en) * 1996-11-08 1998-05-13 Barth, Stefan, Dr. rer. nat. Vector for the bacterial expression of recombinant antibody- and/or cytokine-toxin fusion proteins
CN1368384A (en) * 2001-02-08 2002-09-11 北京迪威华宇生物技术有限公司 Genetically engineered vaccine of MUC-1 antigen for human breast cancer
CN1679930A (en) * 2005-01-31 2005-10-12 中国医学科学院肿瘤医院肿瘤研究所 Human papilloma virus and heat shock protein recombinant protein vaccine and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0841400A1 (en) * 1996-11-08 1998-05-13 Barth, Stefan, Dr. rer. nat. Vector for the bacterial expression of recombinant antibody- and/or cytokine-toxin fusion proteins
CN1368384A (en) * 2001-02-08 2002-09-11 北京迪威华宇生物技术有限公司 Genetically engineered vaccine of MUC-1 antigen for human breast cancer
CN1679930A (en) * 2005-01-31 2005-10-12 中国医学科学院肿瘤医院肿瘤研究所 Human papilloma virus and heat shock protein recombinant protein vaccine and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Li D et al..Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.《Eur J Immunol》.2006,第36卷(第5期),1324-1336. *
任淑萍等.HSP65-MUC1/HSP65抗体免疫复合物对人树突状细胞的活化作用.《吉林大学学报(医学版)》.2005,第31卷(第02期),182-185. *

Also Published As

Publication number Publication date
CN101429251A (en) 2009-05-13

Similar Documents

Publication Publication Date Title
EP1379552B2 (en) Toll-like receptor 5 ligands and methods of use
JP4422903B2 (en) Cancer antigen based on the product of the tumor suppressor gene WT1
JP2557053B2 (en) Tumor necrosis factor purification, production and use
CZ298347B6 (en) Fusion protein of MAGE family, nucleic acid sequence encoding such protein, vector, host cell, vaccine and use of such fuse protein for preparing the vaccine
CN105246496A (en) Salmonella-based vectors for cancer immunotherapy targeting Wilms&#39; tumor gene WT-1
CN108350411B (en) Oral tumor vaccine
CN101429251B (en) Anti-tumor fusion protein, preparation method and application thereof
EA016818B1 (en) Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
AU2013249522A1 (en) Multivalent breast cancer vaccine
CN111856006B (en) Application of mycoplasma bovis secretory protein MbovP274
Ma et al. IL‐24 protects against Salmonella typhimurium infection by stimulating early neutrophil Th1 cytokine production, which in turn activates CD8+ T cells
JPH10500128A (en) Vaccines against mycobacterial infections
CN116970058B (en) Tumor neoantigen polypeptide aiming at TP53 gene R249S mutation and application thereof
CN107823638B (en) Group B meningococcus recombinant chimeric protein vaccine and preparation method thereof
DK2874657T3 (en) HPV / CYAA-BASED CHEMICAL PROTEINS AND THEIR USE FOR INPUT OF IMMUNE RESPONSES TO HPV INFECTION AND HPV-INDUCED DISORDERS
CN106084063B (en) Genetic engineering recombinant TRAIL fusion protein, preparation method and application thereof
CN116732078A (en) Method for preparing tumor-associated antigen NY-ESO-1 by taking pET28a as carrier and application
CN111939247A (en) Protein mixed vaccine for preventing toxoplasmosis of human and animal
Kim et al. CD8+ T cells directed against a peptide Epitope derived from peptidoglycan-associated lipoprotein of Legionella pneumophila confer disease protection
CN112279925B (en) Fusion protein, canine toxoplasma subunit vaccine and vaccine composition thereof
CN105420174A (en) Establishment of genetically engineered bacterium expressing recombined VEGF fusion protein
CN106085932A (en) A kind of structure of the genetic engineering bacterium of VEGF Yu GnRH fusion protein of recombinating
Yan et al. EB virus-positive tumors are inhibited by rBCG expressing hGM-CSF and LMP2A
CN105367662A (en) Fusion protein related to HBV, preparing method thereof and application thereof
CN108611310A (en) A kind of recombination Hsp65 and STEAP1186-193The structure of the genetic engineering bacterium of fusion protein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120523

CF01 Termination of patent right due to non-payment of annual fee